When drug regulators meet later this month to decide whether to let Johnson & Johnson roll out the nation’s third COVID-19 vaccine,
the pharmaceutical giant will almost certainly tout an increasingly important selling point:
its one-shot vaccine has the highest proven efficacy against a worrisome virus variant that emerged in South Africa and has reached the United States.
That’s the view of several vaccine experts interviewed after the government of South Africa this week abandoned plans to use a rival vaccine developed by AstraZeneca and the University of Oxford. |